This novel pathway increases caloric burn at rest, functioning independently of uncoupling protein 1 (UCP1) and AMP-activated protein kinase (AMPK), two traditional targets in metabolic drug development. Unlike many current therapies, SANA remains effective in thermoneutral conditions, making it uniquely suited for consistent metabolic impact.

In preclinical studies, SANA significantly reduced liver fat and improved insulin sensitivity, positioning it as a promising candidate not just for obesity, but for the broader spectrum of cardiometabolic diseases. In a recently published Phase 1a/b clinical trial in Nature Metabolism, SANA was well tolerated and demonstrated early signs of efficacy in reducing body weight and improving glucose metabolism in individuals with overweight and obesity, all within just two weeks of treatment.

SANA represents a new therapeutic paradigm: activating the body’s own energy-burning systems to correct metabolic imbalance and offer patients a novel path to long-term health.